Altis Biosystems

Perform cutting-edge science right from your own lab! Altis provides RepliGut® Planar kits shipped directly to you, containing our primary human intestinal epithelial cells and all the components needed to establish RepliGut® models in your lab. ❓ Not sure where to begin? Chat with one of our expert scientists to guide you through the process and help design your study. Learn more ➡ https://lnkd.in/dCiy2g29 

📣 Check out the latest insights from the "Trust Your Gut" webinar series and workshop held at the NIH last year. Altis' innovative models were highlighted at this event, showcasing the ability of our RepliGut Platform to model toxicology and pharmacokinetics. 👉 Read more: https://lnkd.in/e9aYxY3k 🔦 Go with your gut! https://lnkd.in/er9nEvnJ #Toxicology #RiskAssessment #NAMs #GastrointestinalModels #RegulatoryScience #AlternativesToAnimalTesting #ScienceInnovation #PublicHealth

💡Did you know Altis has developed a primary human jejunum epithelial model optimized for drug transport studies? Unlike conventional Caco-2 cells, RepliGut® Jejunum boasts the following features: 🌟Derived from healthy human stem cells 🔬Delivers more physiologically relevant metabolism 🛡️Produces a functional mucus layer ⏱️Cultured in a shorter timeline for faster results To learn more, download our latest poster presented at last week’s Drug Metabolism Gordon Research Conference! This work delves into gene expression signatures of the RepliGut® Jejunum model and Caco-2 cells. Functional drug transport data highlights our platform’s utility for modeling drug permeability. 👉 https://lnkd.in/eXqS2RCm

#ManuscriptMonday Exciting insights from a recent study using RepliGut® #mucus to study host-pathogen interactions 🦠 Mucus serves a nutrient source for resident microbiota and acts as a physical barrier between intestinal epithelial cells and pathogens; however, bacterial pathogens can exploit this layer to enhance colonization and infection. 🧬 Using mucus produced by Altis’ primary human intestinal epithelial cells, authors discovered that host-derived mucus promotes growth and biofilm formation of the intestinal pathogen Clostridioides difficile. 🧬 Metabolic modeling and growth experiments highlighted the importance of amino acid catabolism, underscoring mucus as a key nutrient source for C. difficile. 🧬 These discoveries deepen the understanding of C. difficile’s interactions with human mucus, shedding light on potential new avenues for combating this pathogen. 🌐 Read more here: https://lnkd.in/e6rjHb3f ❓ Interested in studying bacteria-mucus interactions? Check out our website: https://lnkd.in/eMSzJG9m

📣We are excited to sponsor an upcoming webinar that dives deep into the fascinating world of intestinal organoids. Join us to learn how mini guts are revolutionizing our understanding of digestive physiology and disease. Link to free registration: https://lnkd.in/etfVd4tb

IBD treatment is evolving from broadly immunosuppressive drugs to more precisely targeted therapies. Traditional IBD medications, such as corticosteroids and anti-TNF agents, suppress the immune system broadly, which can lead to various side effects and complications. However, recent advancements have introduced therapies like anti-IL-23 agents, which specifically target interleukin-23, a cytokine involved in the inflammatory process of IBD. These new therapies offer a more precise mechanism of action, potentially leading to better efficacy and fewer side effects. For example, drugs like ustekinumab and risankizumab target IL-23 and have shown promising results in clinical trials. Moreover, the development of human-specific targets necessitates the use of advanced human-based model systems for research and testing. Here are a few ways that human-based models are serving the development of new precision therapies: 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝘁𝗶𝗰 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴: These models provide deeper insights into the molecular and cellular mechanisms of diseases, helping researchers refine drug targets and optimize treatment strategies. 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗩𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆: Human models can be designed to represent diverse genetic backgrounds, allowing for the assessment of drug efficacy and safety across different population subsets. 𝗛𝘂𝗺𝗮𝗻-𝗦𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲𝘀: Human-based models more accurately replicate the complex interactions and responses of the human immune system, providing better insights into how new drugs will perform in actual patients. 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲𝗱 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗧𝗶𝗺𝗲𝗹𝗶𝗻𝗲: By offering more reliable data earlier in the development process, human models can streamline the progression from pre-clinical trials to clinical applications, potentially speeding up the availability of new therapies. The precision of new drugs not only offers new hope for IBD patients by potentially improving symptom control and quality of life but also highlights the importance of continued innovation in drug development. As research progresses, we can anticipate even more refined and effective treatments tailored to the specific needs of IBD patients, underscoring the critical role of human-based model systems in bringing these therapies from the lab to the clinic.

Model systems that recapitulate the intestinal brush border’s functionality are invaluable for drug development. The brush border, a critical structure on the apical surface of epithelial cells lining the small intestine, is key to our understanding of nutrient absorption and digestive health. This specialized structure, with its densely packed microvilli, significantly enhances the surface area of the intestinal lining, facilitating the efficient absorption of essential nutrients. Here’s why replicating the brush border in model systems is so vital: 🌟 Absorption: Microvilli dramatically increase the surface area, enabling the efficient uptake of amino acids, sugars, and fatty acids from digested food. This process is fundamental for nutrient absorption and overall health. 🌟 Enzyme Activity: The brush border membrane is rich in digestive enzymes like lactase, sucrase, and maltase. These enzymes are crucial for breaking down complex carbohydrates into simpler sugars, ready for absorption. 🌟 Protection: Acting as a protective barrier, the brush border defends the underlying cells from harmful substances and pathogens, ensuring the integrity of the intestinal lining. 🌟 Transport: Specialized transport proteins in the brush border membrane facilitate the movement of nutrients and ions into epithelial cells, supporting various physiological functions. Understanding and replicating the intricate functionality of the brush border in model systems is essential for advancing our knowledge in intestinal health and improving therapeutic strategies. #DrugDevelopment #PharmaInnovation #GoWithYourGut #IntestinalHealth #NutrientAbsorption

Jarrett Bliton, PhD will be in NH from July 7th- 12th for the Drug #Metabolism Gordon Research Conference. Stop by his poster to learn more about how we benchmarked gene expression signatures from our RepliGut Jejunum platform against #Caco-2 cells. Looking forward to connecting with other experts in the field. #DMPK #Drugdiscovery Learn more on our website: https://hubs.ly/Q02Dy_NZ0

ICYMI: Jarrett Bliton, PhD's poster presentation at the recent #MPSWorldSummit conference in Seattle, WA last week is available for download! Learn more about our RepliGut® Model applications in #pharmacology and #toxicology screening. Click the link below! Access the poster here: https://hubs.ly/Q02Cf_Vk0 More on our website: https://hubs.ly/Q02CgcPr0

🌟 NE-ADME Meeting 2024 is Off to a Great Start!  We are thrilled to announce that the NE-ADME Meeting 2024 has begun with a series of outstanding presentations, setting the stage for a day full of cutting-edge insights and inspiring discussions. Kicking off the event, Ayman El-Kattan from IFM Therapeutics delivered a captivating opening plenary on the "ECCS Class 3A: Interaction of Gabapentin and Its Analogues with Transporters - A Love-Hate Relationship." Ayman, as usual, was an engaging speaker, providing deep insights into the complexities of transporter interactions. Hema Muralidharan from Moderna followed with her enlightening talk on "Utilizing Ex Vivo Liver Slice Models for Preclinical Evaluation of LNP-Based mRNA Delivery," highlighting innovative approaches in mRNA therapy evaluation. Next, Birk Poller from Novartis, Basel, presented "Liver MPS Model Comparison for Clearance IVIVC," offering a comprehensive comparison of long-term liver models to predict human clearance, which is crucial for drug development. Ben Scruggs from Altis Biosystems captivated the audience with his presentation on "Overcoming Limitations of Caco-2 Cells for ADME Using Adult Human Crypt-Derived Planar Intestinal Epithelium Cultures." His talk underscored the importance of more representative models for accurate drug absorption studies. We wrapped up the morning session with an exciting plenary by Daniel Price from Nimbus Therapeutics on "ADMET in the Age of AI." Daniel's discussion on the transformative potential of AI in ADMET predictions was both thought-provoking and forward-looking. Ruchia Duggal, Ph.D., Vinayak Hosagrahara, Steven Louie, Mitesh Patel, Christopher Rowbottom, Dallas Bednarczyk, Maria Fitzgerald